UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Mersana Therapeutics Inc (MRSN)

Mersana Therapeutics Inc (MRSN)
0.3743 +0.0474 (+14.50%) 14:35 ET [NASDAQ]
0.3733 x 100 0.3748 x 100
Realtime by (Cboe BZX)
0.3733 x 100 0.3748 x 100
Realtime 0.3388 +0.0119 (-) 09:20 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3301
Day High
0.3833
Open 0.3346
Previous Close 0.3269 0.3269
Volume 1,219,335 1,219,335
Avg Vol 2,958,341 2,958,341
Stochastic %K 65.53% 65.53%
Weighted Alpha -86.78 -86.78
5-Day Change +0.0413 (+12.46%) +0.0413 (+12.46%)
52-Week Range 0.2589 - 3.6300 0.2589 - 3.6300
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,742
  • Shares Outstanding, K 124,631
  • Annual Sales, $ 40,500 K
  • Annual Income, $ -69,190 K
  • EBIT $ -73 M
  • EBITDA $ -76 M
  • 60-Month Beta 1.68
  • Price/Sales 1.09
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.56
  • Most Recent Earnings $-0.11 on 03/03/25
  • Next Earnings Date 05/08/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 343.82% ( +105.46%)
  • Historical Volatility 114.56%
  • IV Percentile 85%
  • IV Rank 47.24%
  • IV High 709.61% on 03/28/25
  • IV Low 16.36% on 09/09/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 4,690
  • Open Int (30-Day) 4,471

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.25
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2589 +43.96%
on 04/10/25
Period Open: 0.4254
0.4500 -17.18%
on 03/26/25
-0.0527 (-12.39%)
since 03/21/25
3-Month
0.2589 +43.96%
on 04/10/25
Period Open: 0.5275
0.8178 -54.43%
on 02/06/25
-0.1548 (-29.35%)
since 01/22/25
52-Week
0.2589 +43.96%
on 04/10/25
Period Open: 3.1500
3.6300 -89.73%
on 05/07/24
-2.7773 (-88.17%)
since 04/22/24

Most Recent Stories

More News
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MRSN : 0.3743 (+14.50%)
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

MRSN : 0.3743 (+14.50%)
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

MRSN : 0.3743 (+14.50%)
Mersana Therapeutics to Present at Upcoming Investor Conferences

MRSN : 0.3743 (+14.50%)
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

MRSN : 0.3743 (+14.50%)
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MRSN : 0.3743 (+14.50%)
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

MRSN : 0.3743 (+14.50%)
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

MRSN : 0.3743 (+14.50%)
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

MRSN : 0.3743 (+14.50%)
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

MRSN : 0.3743 (+14.50%)

Business Summary

Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 0.3897
2nd Resistance Point 0.3768
1st Resistance Point 0.3519
Last Price 0.3743
1st Support Level 0.3141
2nd Support Level 0.3012
3rd Support Level 0.2763

See More

52-Week High 3.6300
Fibonacci 61.8% 2.3422
Fibonacci 50% 1.9445
Fibonacci 38.2% 1.5467
Last Price 0.3743
52-Week Low 0.2589

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro